Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priority. This study will evaluate the safety and immunogenicity of a live attenuated monovalent dengue virus vaccine (rDEN3Δ30) in healthy adults with no history of previous flavivirus infection.
Epistemonikos ID: 4f0570b8ab61f88def6b4723cf72fed9f46eb5c8
First added on: Mar 23, 2020